DPP4 and aspiration pneumonitis: There was no difference in the aspiration pneumonia risk with GLP-1RA use compared with either DPP-4 inhibitor use (relative risk 0.95, 95% CI 0.25-1.75) or chronic opioid use (relative risk 0.42, 95% CI 0.15-1.16); however, the incidence of aspiration pneumonia was rare, with 7 (0.05%), 10 (0.07%), and 8 (0.11%) cases in the GLP-1RA, DPP-4 inhibitor, and opioid arms, respectively.